Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease

被引:3
|
作者
Gulbins, Anne [1 ]
Horstmann, Mareike [1 ]
Keitsch, Simone [2 ]
Soddemann, Matthias [2 ]
Wilker, Barbara [2 ]
Wilson, Gregory C. [3 ]
Zeidan, Ryan [4 ]
Hammer, Gary D. [5 ]
Daser, Anke [6 ]
Bechrakis, Nikolaos E. [7 ]
Goertz, Gina-Eva [1 ]
Eckstein, Anja [1 ]
机构
[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Ophthalmol, Mol Ophthalmol, Essen, Germany
[2] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany
[3] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH USA
[4] Sling Therapeut Inc, Ann Arbor, MI USA
[5] Univ Michigan, Endocrine Oncol Program, Ann Arbor, MI 48109 USA
[6] Univ Duisburg Essen, Univ Hosp Essen, Dept Otorhinolaryngol Head & Neck Surg, Essen, Germany
[7] Univ Duisburg Essen, Univ Hosp Essen, Dept Ophthalmol, Essen, Germany
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
bone marrow; linsitinib; autoimmunity; inflammation; small molecule IGF-1R antagonist GD: Graves' disease; thyroid eye disease (TED); FACTOR-I RECEPTOR; L-ARGININE; IGF-1; RECEPTOR; T-CELLS; OPHTHALMOPATHY; OSTEOPONTIN; METABOLISM; EPIDEMIOLOGY; PATHOGENESIS; FIBROBLASTS;
D O I
10.3389/fendo.2023.1252727
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Graves' disease is an autoimmune disorder caused by auto-antibodies against the thyroid stimulating hormone receptor (TSHR). Overstimulation of the TSHR induces hyperthyroidism and thyroid eye disease (TED) as the most common extra thyroidal manifestation of Graves' disease. In TED, the TSHR cross talks with the insulin-like growth factor 1 receptor (IGF-1R) in orbital fibroblasts leading to inflammation, deposition of hyaluronan and adipogenesis. The bone marrow may play an important role in autoimmune diseases, but its role in Graves' disease and TED is unknown. Here, we investigated whether induction of experimental Graves' disease and accompanying TED involves bone marrow activation and whether interference with IGF-1R signaling prevents this activation.Results: Immunization of mice with TSHR resulted in an increase the numbers of CD4-positive T-lymphocytes (p <= 0.0001), which was normalized by linsitinib (p = 0.0029), an increase of CD19-positive B-lymphocytes (p= 0.0018), which was unaffected by linsitinib and a decrease of GR1-positive cells (p= 0.0038), which was prevented by linsitinib (p= 0.0027). In addition, we observed an increase of Sca-1 positive hematopietic stem cells (p= 0.0007) and of stromal cell-derived factor 1 (SDF-1) (p <= 0.0001) after immunization with TSHR which was prevented by linsitinib (Sca-1: p= 0.0008, SDF-1: p <= 0.0001). TSHR-immunization also resulted in upregulation of CCL-5, IL-6 and osteopontin (all p <= 0.0001) and a concomitant decrease of the immune-inhibitory cytokines IL-10 (p= 0.0064) and PGE2 (p <= 0.0001) in the bone marrow (all p <= 0.0001). Treatment with the IGF-1R antagonist linsitinib blocked these events (all p <= 0.0001). We further demonstrate a down-regulation of arginase-1 expression (p= 0.0005) in the bone marrow in TSHR immunized mice, with a concomitant increase of local arginine (p <= 0.0001). Linsitinib induces an upregulation of arginase-1 resulting in low arginase levels in the bone marrow. Reconstitution of arginine in bone marrow cells in vitro prevented immune-inhibition by linsitinib.Conclusion: Collectively, these data indicate that the bone marrow is activated in experimental Graves' disease and TED, which is prevented by linsitinib. Linsitinib-mediated immune-inhibition is mediated, at least in part, by arginase-1 up-regulation, consumption of arginine and thereby immune inhibition.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Thyroid surgery for Graves' disease and Graves' ophthalmopathy
    Liu, Zi Wei
    Masterson, Liam
    Fish, Brian
    Jani, Piyush
    Chatterjee, Krishna
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (11):
  • [32] Hyperthyroidism (Graves' thyroid disease)
    不详
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1910, 55 : 2154 - 2157
  • [33] Thyroid Dermopathy in Graves' Disease
    Arjunan, Durairaj
    Bhadada, Sanjay K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (25): : 2376 - 2376
  • [34] Maltoma of the thyroid and Graves' disease
    Djrolo, F
    Gervaise, N
    Combe, H
    Linassier, C
    Lhuintre, Y
    Lecomte, P
    ANNALES D ENDOCRINOLOGIE, 2001, 62 (05) : 442 - 445
  • [35] Thyroid cancer in Graves' disease
    Cichon, S
    Barczynski, M
    Barczynski, ML
    Anielski, R
    Hladki, W
    PROCEEDINGS EUROSURGERY 2000, 2000, : 99 - 102
  • [36] Thyroid cancer in Graves' disease: is surgery the best treatment for Graves' disease?
    Tamatea, Jade A. U.
    Tu'akoi, Kelson
    Conaglen, John V.
    Elston, Marianne S.
    Meyer-Rochow, Goswin Y.
    ANZ JOURNAL OF SURGERY, 2014, 84 (04) : 231 - 234
  • [37] Relapse of Graves' disease after successful allogeneic bone marrow transplantation
    L-T Hsiao
    J-H Liu
    C-C Yen
    W-S Wang
    FS Fan
    T-J Chiou
    P-M Chen
    Bone Marrow Transplantation, 2001, 28 : 1151 - 1153
  • [38] Relapse of Graves' disease after successful allogeneic bone marrow transplantation
    Hsiao, LT
    Liu, JH
    Yen, CC
    Wang, WS
    Fan, FS
    Chiou, TJ
    Chen, PM
    BONE MARROW TRANSPLANTATION, 2001, 28 (12) : 1151 - 1153
  • [39] Thyroid eye disease: current and potential medical management
    Jessica M. Pouso-Diz
    Jose M. Abalo-Lojo
    Francisco Gonzalez
    International Ophthalmology, 2020, 40 : 1035 - 1048
  • [40] Thyroid eye disease: current and potential medical management
    Pouso-Diz, Jessica M.
    Abalo-Lojo, Jose M.
    Gonzalez, Francisco
    INTERNATIONAL OPHTHALMOLOGY, 2020, 40 (04) : 1035 - 1048